Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 2/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CD38 | P28907 | 1/20 | 0.34 |
| ▸ | SCD5 | Q86SK9 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3088068 | 0.85 | GRIN1 (0.37) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL21503557 | 0.81 | CYP2E1 (0.41) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL30630670 | 0.77 | LOXL2 (0.52) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL29525334 | 0.77 | CD38 (0.40) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL15514881 | 0.77 | CD38 (0.40) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL1272973 | 0.77 | GRIN1 (0.40) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL844759 | 0.77 | GRIN1 (0.37) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL1272312 | 0.77 | CD38 (0.40) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL507313 | 0.77 | LOXL2 (0.52) | GRIN1GRIN2BFAAHALDH1A1CD38 | |
| SCHEMBL8403256 | 0.77 | ALDH1A1 (0.48) | GRIN1GRIN2BFAAHALDH1A1CD38 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9532985-B2 | Tetrahydroquinoline derivatives for treating post-traumatic stress disorders | ACTELION PHARMACEUTICALS LTD. (CH) | 2017-01-03 | — | — | US | disclosed |
| EP-2207550-B1 | TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-12-11 | — | — | EP | disclosed |
| US-20100234420-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS | IDORSIA PHARMACEUTICALS LTD (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2207550-A2 | TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS | Actelion Pharmaceuticals Ltd. (CH) | 2010-07-21 | — | — | EP | disclosed |
| WO-2009047723-A2 | TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS | ACTELION PHARMACEUTICALS LTD (CH) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234420-A1 | TETRAHYDROQUINOLINE DERIVATIVES FOR TREATING POST-TRAUMATIC STRESS DISORDERS | CRH, HTR2C, CRHR1 | GRIN1 108/4885GRIN2B 139/4885FAAH 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.